Eisai Clinical Trials
Study Overview
E7080
lenvatinib
NCT02432274, 2013-005534-38
Dec 2014 - Jul 2022
Refractory or relapsed solid malignancies
1. Cohort 1: Recommended Dose (RD) of Lenvatinib [Time Frame: Cycle 1 (28 days)]
2. Cohort 2A: Number of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) [Time Frame: From date of first dose of study drug until first documentation of PD or death, whichever occurred first (until the data cut-off date, 31 May 2019)]
2. Cohort 2A: Number of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) [Time Frame: From date of first dose of study drug until first documentation of PD or death, whichever occurred first (until the data cut-off date, 31 May 2019)]
-
Males and females 2 Years to 25 Years (Child, Adult)
-
Completed -
Phase 1 / 2
France, Germany, Italy, Spain, United Kingdom, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR